The promise of immunisation against rotavirus

Archives of Disease in Childhood

Volumn 97, Issue 8, 2012, Pages 736-740

  Marlow, Robin D ^a   Finn, Adam ^b  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNITY; IMMUNIZATION; INFECTIOUS DIARRHEA; NONHUMAN; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION;

CHILD HEALTH SERVICES; CHILD, PRESCHOOL; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; WORLD HEALTH;

EID: 84864648190     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-301472     Document Type: Review

References (60)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerging Infect Dis 2003;9:565-72. (Pubitemid 36529515)
2. Tate JE, Burton AH, Boschi-Pinto C, et al. Estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:136-41.
3. Iturriza Gómara M, Simpson R, Perault AM, et al. Structured surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common viral gastroenteric pathogens. Epidemiol Infect 2008;136:23-33.
4. Jit M, Pebody R, Chen M, et al. Estimating the number of deaths with rotavirus as a cause in England and Wales. Hum Vaccin 2007;3:23-6.
5. Health Protection Agency. Epidemiological data on rotavirus infections. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Rotavirus/ EpidemiologicalData/rota-DataEwMonth/ (accessed 13 Jun 2011).
6. Harris JP, Jit M, Cooper D, et al. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 2007;25:3962-70. (Pubitemid 46616997)
7. Nicholson KG, McNally T, Silverman M, et al. Rates of hospitalisation for infl uenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006;24:102-8. (Pubitemid 41721106)
8. Booy R, Hodgson SA, Slack MP, et al. Invasive Haemophilus infl uenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993;69:225-8. (Pubitemid 23267368)
9. Bishop RF, Davidson GP, Holmes IH, et al. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;2:1281-3.
10. Gentsch JR, Laird AR, Bielfelt B, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005;192 Suppl 1:S146-59. (Pubitemid 41193116)
11. Desselberger U, Huppertz HI. Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 2011;203:188-95.
12. Zheng BJ, Chang RX, Ma GZ, et al. Rotavirus infection of the oropharynx and respiratory tract in young children. J Med Virol 1991;34:29-37.
13. Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 2000;19:S103-5.
14. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8. (Pubitemid 26338732)
15. Santosham M, Letson GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991;163:483-7.
16. Kapikian AZ, Hoshino Y, Chanock RM, et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996;174 Suppl 1:S65-72. (Pubitemid 26293124)
17. Joensuu J, Koskenniemi E, Pang XL, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-9. (Pubitemid 127445093)
18. Pérez-Schael I, Guntiñas MJ, Pérez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-7.
19. Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine-United States 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:577-81.
20. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72. (Pubitemid 32167870)
21. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001;20:410-6. (Pubitemid 32294750)
22. Simonsen L, Morens D, Elixhauser A, et al. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 2001;358:1224-9. (Pubitemid 33010847)
23. Simonsen L, Viboud C, Elixhauser A, et al. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005;192 Suppl 1:S36-43. (Pubitemid 41193100)
24. World Health Organization. Global Advisory Committee on Vaccine Safety, 1-2 December 2005, Wkly Epidemiol Rec 2006;81:13-20.
25. Robinson CG, Hernanz-Schulman M, Zhu Y, et al. Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible? J Infect Dis 2004;189:1382-7. (Pubitemid 38543586)
26. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. (Pubitemid 43048947)
27. Perez-Schael I, Linhares AC, Vesikari T, et al. Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16-19 December 2005.
28. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757-63. (Pubitemid 350137490)
29. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362:289-98.
30. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent humanbovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. (Pubitemid 43048948)
31. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376:615-23.
32. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376:606-14.
33. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29:3061-6.
34. Velazquez FR, Colindres R, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the human rotavirus vaccine in Mexico: an interim analysis. Acta Paediatr 2010;99(Suppl 462):PP106.
35. Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011;364:2283-92.
36. Steele AD, De Vos B, Tumbo J, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010;28:6542-8.
37. Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012;307:598-604.
38. World Health Organization. Global Advisory Committee on Vaccine Safety, December 2011. Wkly Epidemiol Rec 2012;87:53-60.
39. US Food and Drug Administration. Early Communication on Rotarix Vaccine, 22 March 2010. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm205540.htm (accessed 13 Jun 2011).
40. European Medicines Agency-Committee for Medicinal Products for Human Use Extraordinary Meeting, London, 25 March 2010. http://www.emea.europa.eu/docs/en- GB/document-library/Press-release/2010/03/WC500078280.pdf (accessed 29 April 2012).
41. McClenahan SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine 2011;29:4745-53.
42. US Food and Drug Administration. Update on Recommendations for the Use of Rotavirus Vaccines, 14 May 2010. http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm212140.htm (accessed 13 Jun 2011).
43. European Medicines Agency. Press release, 22 July 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/07/ WC500094972.pdf (accessed Mar 2012).
44. World Health Organization. Global Advisory Committee on Vaccine Safety, 16-17 June 2010. Wkly Epidemiol Rec 2010;85:285-92.
45. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009;84:232-6.
46. Braeckman T, Van Herck K, Raes M, et al. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011;30:S21-4.
47. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010;125:e208-13.
48. Lopman BA, Curns AT, Yen C, et al. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011;204:980-6.
49. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011;365:772-3.
50. Field EJ, Vally H, Grimwood K, et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010;126:e506-12.
51. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009;301:2243-51.
52. Justino MC, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatr Infect Dis J 2011;30:396-401.
53. Paulke-Korinek M, Rendi-Wagner P, Kundi M, et al. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010;29:319-23.
54. Office for National Statistics. Mid-2010 Population Estimates Analysis Tool. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition= tcm%3A77-230167 (accessed 4 Oct 2011).
55. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007;25:3971-9. (Pubitemid 46616994)
56. Lorgelly PK, Joshi D, Iturriza Gómara M, et al. Infantile gastroenteritis in the community: a cost-of-illness study. Epidemiol Infect 2008;136:34-43.
57. Lorgelly PK, Joshi D, Iturriza Gómara M, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008;136:44-55.
58. Department of Health. Joint Committee on Vaccination and Immunisation Statement, 20 February 2009. http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/@dh/@ab/documents/digitalasset/dh-095177.pdf (accessed 13 Jun 2011).
59. Martin A, Batty A, Roberts JA, et al. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009;27:4520-8.
60. Campbell DI. Comment on: the cost effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2011;29:3731; author reply 3732-3.